NTU281

NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes[1][2].

Product Specifications

CAS Number

[815619-12-6]

UNSPSC

12352005

Target

Apoptosis; Glutaminase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ntu281.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H](C(N[C@@H](CCC(C[S+](C)C)=O)C(O)=O)=O)CC1=CC=CC=C1)OCC2=CC=CC=C2

Molecular Formula

C25H31N2O6S

Molecular Weight

487.59

References & Citations

[1]Hornigold N, et al. Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy. Lab Invest. 2013 May;93 (5) :553-65.|[2]Huang L, et al. Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy? Nephrol Dial Transplant. 2010 Dec;25 (12) :3897-910.